We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 22 DECEMBER 2017
Post-Priority-Date Evidence May Be Relevant To 35 U.S.C. § 112 Inquiry
Carlson, Caspers, Vandenburgh, Lindquist & Schuman, P.A.
Recently, the Federal Circuit reversed a jury decision upholding the validity of two Amgen patents directed to a large genus of antibodies that reduce LDL cholesterol.
United StatesIntellectual Property








